Free Trial
NASDAQ:ARTV

Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Artiva Biotherapeutics logo
$2.76 +0.12 (+4.55%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$2.68 -0.07 (-2.72%)
As of 08/8/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Artiva Biotherapeutics Stock (NASDAQ:ARTV)

Key Stats

Today's Range
$2.63
$2.99
50-Day Range
$1.47
$3.60
52-Week Range
$1.47
$17.31
Volume
72,275 shs
Average Volume
186,397 shs
Market Capitalization
$67.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.80
Consensus Rating
Buy

Company Overview

Artiva Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

ARTV MarketRank™: 

Artiva Biotherapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 581st out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Artiva Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Artiva Biotherapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Artiva Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Artiva Biotherapeutics are expected to grow in the coming year, from ($4.95) to ($2.83) per share.

  • Price to Book Value per Share Ratio

    Artiva Biotherapeutics has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ARTV.
  • Dividend Yield

    Artiva Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Artiva Biotherapeutics does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ARTV.
  • News Sentiment

    Artiva Biotherapeutics has a news sentiment score of -0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Artiva Biotherapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 6 people have searched for ARTV on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Artiva Biotherapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Artiva Biotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.40% of the stock of Artiva Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Artiva Biotherapeutics' insider trading history.
Receive ARTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTV Stock News Headlines

Artiva (ARTV) Q2 Loss Widens 19.7%
Amazon’s big Bitcoin embarrassment
Bitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.
Artiva Biotherapeutics Rings the Closing Bell
See More Headlines

ARTV Stock Analysis - Frequently Asked Questions

Artiva Biotherapeutics' stock was trading at $10.08 on January 1st, 2025. Since then, ARTV shares have decreased by 72.6% and is now trading at $2.76.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) issued its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.87) EPS for the quarter, missing analysts' consensus estimates of ($0.84) by $0.03.

Artiva Biotherapeutics (ARTV) raised $167 million in an initial public offering (IPO) on Friday, July 19th 2024. The company issued 13,920,000 shares at $12.00 per share.

Top institutional shareholders of Artiva Biotherapeutics include Geode Capital Management LLC (0.65%), Y Intercept Hong Kong Ltd (0.13%) and Ground Swell Capital LLC (0.10%). Insiders that own company stock include Yong-Jun Huh and Global Strategic Fund I Venbio.
View institutional ownership trends
.

Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI).

Company Calendar

Last Earnings
8/06/2025
Today
8/10/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARTV
Previous Symbol
NASDAQ:ARTV
CIK
1817241
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

High Price Target
$21.00
Low Price Target
$12.00
Potential Upside/Downside
+544.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$65.37 million
Net Margins
N/A
Pretax Margin
-26,045.02%
Return on Equity
-42.60%
Return on Assets
-37.76%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.84
Quick Ratio
13.93

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.11 per share
Price / Book
0.45

Miscellaneous

Outstanding Shares
24,394,000
Free Float
19,174,000
Market Cap
$67.33 million
Optionable
N/A
Beta
N/A

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ARTV) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners